Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Capital Employed (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Return on Capital Employed for 15 consecutive years, with 0.07% as the latest value for Q3 2025.

  • On a quarterly basis, Return on Capital Employed rose 77.0% to 0.07% in Q3 2025 year-over-year; TTM through Sep 2025 was 0.07%, a 77.0% increase, with the full-year FY2024 number at 0.16%, up 99.0% from a year prior.
  • Return on Capital Employed was 0.07% for Q3 2025 at Gyre Therapeutics, up from 0.06% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.28% in Q1 2023 to a low of 2.65% in Q2 2023.
  • A 5-year average of 0.64% and a median of 0.51% in 2024 define the central range for Return on Capital Employed.
  • Biggest YoY gain for Return on Capital Employed was 259bps in 2023; the steepest drop was -249bps in 2023.
  • Gyre Therapeutics' Return on Capital Employed stood at 1.66% in 2021, then soared by 89bps to 0.19% in 2022, then tumbled by -553bps to 1.23% in 2023, then soared by 112bps to 0.15% in 2024, then plummeted by -53bps to 0.07% in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Return on Capital Employed are 0.07% (Q3 2025), 0.06% (Q2 2025), and 0.1% (Q1 2025).